It is suggested that hepcidin downregulates ferroportin expression and dominantly controls the iron export activity of ferroportin in patients with cancer, Alzheimer’s disease, and anemia of chronic inflammation [28,29,30]. This evidence concerns the gene SLC40A1 and early-onset autosomal dominant Alzheimer disease.